Medtronic Announces FDA Approval Of SenSight Directional Lead System For Treating Movement Disorders

Medtronic said it will launch the SenSight DBS in the US after winning FDA approval. The total DBS market is expected to exceed $1bn by 2024, according to Meddevicetracker.

Brain

Medtronic plc announced on 7 June the US Food and Drug Administration approved its SenSight directional lead system used in deep brain stimulation (DBS) for treating symptoms associated with movement disorders such as Parkinson’s disease, dystonia and essential tremor, and medically refractory epilepsy.

DBS is delivered from a small pacemaker-like device that sends electrical signals through thin wires, known as leads, to a...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation